MAR 10, 2020 8:13 PM PDT

Chemo more effective with Intralipid treatment

A study published recently in Scientific Reports suggests a novel technique to make chemotherapy more effective. The technique couples chemotherapy nanodrugs with a nutritional supplement called Intralipid to decrease side effects during treatment and cut the quantify of drugs needed for treatment. Coming from Carnegie Mellon University and Taiwan's National Health Research Institutes, the technique was originally developed by Emeritus Professor of Biological Sciences Chien Ho in 2015 and has since advanced in its progress. It will begin early-stage clinical trials in the near future.

One of the complications of chemotherapy stems from the difficulties of drug delivery. Although certain nanodrugs are indeed quite good at destroying cancer cells, in many cases, very small quantities of the drugs actually reach cancer tumor cells. That’s certainly the case with paclitaxel, a nanodrug that is used in chemotherapy. Estimates report that less than 1% of the drug reaches tumors, while the rest of it gets taken up by healthy cells in the individual’s organs, resulting in toxic side-effects.

In this study, the researchers looked at a specific kind of paclitaxel called Abraxane. They wanted to see how pairing Intralipid nutrient supplements with Abraxane would affect cells. "The combination of anti-cancer nanodrugs with Intralipid enhances the inhibition of tumor growth and may serve as a novel strategy to improve therapeutic efficacy in treating cancers in clinical practice," observed Ho.  

Additionally, the researchers figured out that administering the supplement prior to chemotherapy also prevented damage to monocytic white blood cells. In tests with pancreatic, breast, and lung cancer cells in mice models, they found that the presence of Intralipid with the Abraxane acted to convert macrophages into the M1 phenotype, thereby encouraging the generation of macrophages that kill tumor cells.

Ultimately, the goal of this research is to reduce the side effects brought on by chemotherapy and cut the amounts of drugs that are necessary during treatment while maintaining effectiveness. These end goals have very real implications both financially and for patients’ health and well-being. That’s why the last conclusion from this study is so encouraging: the researchers showed that it is possible to pretreat with Intralipid and then give only half the standard dosage of Abraxane without losing any effectiveness.

"By decreasing the amount of Abraxane needed in treating cancers, we can protect the organs from some of the chemical damage done by the drug," elaborated Ho.

The presence of Intralipid with the Abraxane converts macrophages into the M1 phenotype. Photo: Pixabay

The researchers believe their technique could hold significant implications for other nanodrug treatments. "This new nanodrug delivery method is a general one and can be applied to other approved and in-development nanodrugs without any modifications to the drugs or their carriers," said Ho. "This drug delivery method can reduce the amount of drugs needed for treatment, improving the quality of life for patients and reducing the cost of treatment with these expensive drugs."

Sources: Scientific Reports, Eureka Alert!

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUL 30, 2020
Cardiology
Protecting the Heart Against Cardiotoxicity
JUL 30, 2020
Protecting the Heart Against Cardiotoxicity
Doxorubicin is a potent chemotherapy drug used for many different cancers. Unfortunately, like all chemotherapies, doxor ...
JUL 25, 2020
Cancer
Researchers use algorithm to develop comprehensive list of pediatric cancer-causing mutations
JUL 25, 2020
Researchers use algorithm to develop comprehensive list of pediatric cancer-causing mutations
A breakthrough study published recently in Science Advances reports the creation of a list of mutations in the noncoding ...
JUL 30, 2020
Cancer
Researchers say DBT doesn't serve women with "extremely dense" breasts
JUL 30, 2020
Researchers say DBT doesn't serve women with "extremely dense" breasts
When you undergo screening for breast cancer, you usually have to have a mammogram, an x-ray that looks for abnormal mas ...
AUG 03, 2020
Cancer
Improving Diagnostics in Breast Cancer
AUG 03, 2020
Improving Diagnostics in Breast Cancer
Diagnostics is one of the essential tools in a physician’s toolkit. A good diagnostic test can identify whether a ...
AUG 04, 2020
Cancer
Commonly used pesticides, approved by EPA, linked to mammary gland tumors
AUG 04, 2020
Commonly used pesticides, approved by EPA, linked to mammary gland tumors
In an analysis of how regulators review pesticides for their potential to cause cancer, researchers at Silent Spring Ins ...
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
Loading Comments...